Quadrant Capital Group 13F: Cuts Alcon (ALC) Stake by $1.5M

Quadrant Capital Group lowered its stake in Alcon Inc. ALC by 44.1% during the third quarter, according to a Form 13F filing with the SEC on October 20, 2026. The firm sold 23,173 shares of the eye care company, ending the period with 29,363 shares valued at approximately $1.85 million.

ALC Alcon Inc.

$67.43 ▼ -12.68% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in Quadrant Capital Group's Alcon Position

Quadrant Capital Group scaled back its exposure to Alcon Inc. ALC by cutting its holdings nearly in half. The fund held 52,536 shares prior to the filing. After the sale of 23,173 shares, its remaining position stands at 29,363 shares with a reported value of $1,849,869.

Other Institutional Activity in Alcon

Other major investors have adjusted their positions in Alcon Inc. ALC as well. Legal & General Group grew its holdings by 53,234 shares, ending with 3,950,897 shares worth about $267.12 million. Aristotle Capital Management reduced its stake by 481,233 shares, leaving it with 10,584,374 shares valued at roughly $710.21 million. Vanguard Group boosted its holdings by 269,343 shares to end with 21,464,480 shares worth about $1.45 billion. Meanwhile, Vanguard Asset Management and Schonfeld Strategic Advisors opened new positions in the medical product maker during the first half of the year.

Alcon Inc. Stock Up 2.5%

Alcon Inc. ALC recently traded around $67.83, matching its closing price of $67.83 on the October 20, 2026 filing date. The stock trades below its 50-day moving average of $68.36 and below its 200-day moving average of $72.42. Shares sit 22.6% below their 52-week high of $87.64 and 9.7% above their 52-week low of $61.84.

Recent Earnings

Alcon Inc. posted trailing twelve-month revenue of $10.86 billion and earnings of $1.32 per share, with a net profit margin of 5.9% and a return on equity of 2.9%. Revenue grew 8.7% compared to the prior year period. The company's next earnings report is scheduled for November 10, 2026.

Dividend

Alcon pays an annual dividend rate of $0.36 per share, which translates to a dividend yield of 0.54% based on recent trading levels. The payout ratio sits at 26.6% of earnings.

Analysts Set New Price Targets

Wall Street research firms have updated their outlooks on Alcon Inc. ALC in recent months. On August 12, 2026, JP Morgan maintained a neutral rating with a price target of $78.40. Needham reiterated a buy rating with a $98.00 target on September 15, 2026. Jefferies maintained a buy rating while lowering its target from $95.00 to $85.00 on September 22, 2026. Barclays initiated coverage with an equal-weight rating and a $70.00 target on October 7, 2026. BTIG maintained a buy rating while adjusting its target from $82.00 to $74.00 on October 12, 2026. Analysts currently hold a consensus buy rating on the stock with a mean price target of $82.73.

About Alcon

Headquartered in Geneva, Switzerland, Alcon Inc. operates as a global medical company focused on eye care products. The business runs through two main divisions: Surgical and Vision Care. The surgical segment provides advanced equipment, intraocular lenses, and consumables used in procedures like cataract and refractive surgery. The vision care segment offers contact lenses and eye drop products. Institutional ownership shifts in the company come as management works to expand its footprint in global eye health markets.

Bottom Line

Investors are watching for Alcon Inc.'s next earnings report on November 10, 2026, to gauge ongoing revenue growth and margin trends across its surgical and vision care segments.